Colchicine in Patients with Chronic Coronary Disease
Author(s) -
Stefan M. Nidorf,
Aernoud T.L. Fiolet,
Arend Mosterd,
John W. Eikelboom,
Astrid Schut,
Tjerk S.J. Opstal,
Salem H.K. The,
Xiao-Fang Xu,
Mark A. Ireland,
Timo Lenderink,
Donald Latchem,
Pieter A.M. Hoogslag,
Anastazia Jerzewski,
Peter R Nierop,
Alan Whelan,
Randall Hendriks,
Henk P. Swart,
Jeroen Schaap,
Aaf F.M. Kuijper,
M. W. J. van Hessen,
Pradyot Saklani,
Isabel Tan,
Angus G Thompson,
Allison Morton,
Chris Judkins,
Willem A. Bax,
Maurits T. Dirksen,
Marco Alings,
Graeme J. Hankey,
Charley A. Budgeon,
Jan G.P. Tijssen,
Jan H. Cornel,
Peter L. Thompson
Publication year - 2020
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa2021372
Subject(s) - colchicine , medicine , myocardial infarction , cardiology , coronary heart disease , disease , coronary disease
Evidence from a recent trial has shown that the antiinflammatory effects of colchicine reduce the risk of cardiovascular events in patients with recent myocardial infarction, but evidence of such a risk reduction in patients with chronic coronary disease is limited.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom